Dr Grzegorz S. Nowakowski muses on the unmet needs of patients with DLBCL and the emerging treatment options he looks forward to.
Physicians Respond to 5-Year Tafasitamab/Lenalidomide Data for R/R DLBCL
June 6th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen J. Schuster, MD, discussed the use of tafasitamab plus lenalidomide in patients with diffuse large B-cell lymphoma including managing adverse events and treating patients after disease progression.
Read More
Long-Term Combination Data Show Most Benefit in Second-Line DLBCL
May 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen A. Schuster, MD, discussed the 5-year outcomes of the L-MIND trial of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Roundtable Discussion: Khan Reviews Systemic Therapy for Relapsed/Refractory DLBCL
April 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus Khan, MD, discussed the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was referred for chimeric antigen receptor T-cell therapy and was place on a waiting list for treatment.
Read More
Reviewing Key Efficacy and Safety Data for Tafasitamab Plus Lenalidomide in DLBCL
April 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed the study results and practical considerations for the use of tafasitamab plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
2 Clarke Drive
Cranbury, NJ 08512